Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
← catalyst calendarNCT04895436 · readout ≤ 102 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →. With F. Hoffmann-La Roche Ltd; German CLL Study Group (GCLLSG); Dana-Farber Cancer Institute.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
75estimated
Sites
58
Countries
Australia, Austria, Brazil +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-03-28 | actual | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2021-05-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Lymphocytic Leukemia (CLL)
Interventions
- Drug: Venetoclax — also filed as Venclexta, ABT-199, GDC-0199
- Drug: Obinutuzumab — also filed as GA101, Gazyva
Primary outcome
what the primary-completion date above is the date OFOverall response (OR) in Cohort 1 after end of combination treatment
measured 9 months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed